DNA Methylation profiles as predictors of recurrence in non muscle invasive bladder cancer: an MS-MLPA approach

Valentina Casadio¹, Chiara Molinari¹, Daniele Calisti¹, Michela Tebaldi¹, Roberta Gunelli², Luigi Serra³, Fabio Falcini⁵, Chiara Zingaretti⁴, Rosella Silvestrini¹, Dino Amadori⁵ and Wainer Zoli¹*

Abstract

Background: Although non muscle invasive bladder cancer (NMIBC) generally has a good long-term prognosis, up to 80% of patients will nevertheless experience local recurrence after the primary tumor resection. The search for markers capable of accurately identifying patients at high risk of recurrence is ongoing. We retrospectively evaluated the methylation status of a panel of 24 tumor suppressor genes (TIMP3, APC, CDKN2A, MLH1, ATM, RARB, CDKN2B, HIC1, CHFR, BRCA1, CASP8, CDKN1B, PTEN, BRCA2, CD44, RASSF1, DAPK1, FHIT, VHL, ESRI, TP73, IGSF4, GSTP1 and CDH13) in primary lesions to obtain information about their role in predicting local recurrence in NMIBC.

Methods: Formaldehyde-fixed paraffin-embedded (FFPE) samples from 74 patients operated on for bladder cancer were analyzed by methylation-specific multiplex ligation-dependent probe amplification (MS-MLPA): 36 patients had relapsed and 38 were disease-free at the 5-year follow up. Methylation status was considered as a dichotomous variable and genes showing methylation \( \geq 20\% \) were defined as “positive”.

Results: Methylation frequencies were higher in non recurring than recurring tumors. A statistically significant difference was observed for HIC1 \((P = 0.03)\), GSTP1 \((P = 0.02)\) and RASSF1 \((P = 0.03)\). The combination of the three genes showed 78% sensitivity and 66% specificity in identifying recurrent patients, with an overall accuracy of 72%.

Conclusions: Our preliminary data suggest a potential role of HIC1, GSTP1 and RASSF1 in predicting local recurrence in NMIBC. Such information could help clinicians to identify patients at high risk of recurrence who require close monitoring during follow up.

Keywords: Non muscle invasive bladder cancer (NMIBC), Gene methylation profile, Recurrence

Background

Although superficial bladder cancer generally has a good long-term prognosis, up to 80% of patients will have local recurrence within 5 years of the primary tumor resection [1]. After transurethral resection of bladder cancer (TURB), standard follow up involves numerous cystoscopies with consequently high healthcare costs and low patient compliance. Multiplicity, tumor size and prior relapse rate are the only recurrence-related parameters currently available for monitoring patients with bladder cancer [1], but such information would not seem to be accurate enough to ensure an adequate follow-up of individuals with stage Ta-T1 non muscle invasive bladder cancer (NMIBC). It would thus be extremely useful for clinicians to have new biological markers that can predict recurrence more accurately.

The role of epigenetic alterations in the carcinogenesis of solid tumors has been intensively investigated over the last ten years [2,3]. DNA methylation at CpG rich regions often occurs at tumor suppressor gene promoters, frequently producing a reduction in the expression of target genes. An increasing number of papers are being published on the role of gene methylation and its potential clinical application in human tumors [4]. Methylation seems to be an early event in the development of a number of solid tumors including bladder cancer [5,6] and can
thus be regarded as an early sign of cancer before the disease becomes muscle-invasive. Methylated tumor suppressor genes such as APC, RARB2, BRCA1 have recently been indicated as valid diagnostic markers for NMIBC [7-10]. A number of papers have also focused on the role of methylation as a prognostic marker, but it is not clear which methylated genes can accurately predict recurrence. Some studies have hypothesized hypermethylation of tumor suppressor genes, such as TIMP3, as a good prognostic marker [11,12], while others have indicated hypermethylated E-cadherin, p16, p14, RASSF1, DAPK, APC, alone or in different combinations, as potential markers of early recurrence and poor survival [13-15].

In the present study we evaluated the methylation status of a panel of 24 genes (TIMP3, APC, CDKN2A, MLH1, ATM, RARB, CDKN2B, HIC1, CHFR, BRCA1, CASP8, CDKN1B, PTEN, BRCA2, CD44, RASSF1, DAPK1, FHIT, VHL, ESR1, TP73, IGSF4, GSTP1 and CDH13) in superficial bladder cancer to determine their

| Table 1 Case series | Patients |
|---------------------|----------|
|                     | Recurrent | Non recurrent |
| Sex                 |           |
| Male                | 33        | 32           |
| Female              | 3         | 6            |
| Age, years          |           |
| <70                 | 19        | 12           |
| ≥70                 | 17        | 26           |
| Grade               |           |
| Low                 | 27        | 28           |
| High                | 9         | 10           |
| Stage               |           |
| Ta                  | 30        | 31           |
| T1                  | 6         | 7            |

Figure 1 Electropherogram relating to a) undigested and b) digested HT1376 samples with methylation of APC and RASSF1 genes.
ability to predict recurrence. Although methylation of some of these genes has already been investigated in bladder cancer [11-15], its relevance as an indicator of recurrence has yet to be confirmed. We used the relatively new methodology of methylation specific multiplex ligation dependent probe amplification (MS-MLPA) to evaluate epigenetic gene profiles. This approach permits methylation analysis of multiple targets in a single experiment [16,17] and has been successfully used to evaluate the diagnostic or prognostic relevance of different markers in several tumor types such as lung [18], rectal [19], breast [20] and recently, bladder cancers [7,8].

**Methods**

**Case series (retrospective cohort study)**

Tissue samples from 74 patients (65 males, 9 females) submitted to transurethral resection of primary bladder cancer at the Department of Urology of Morgagni-Pierantoni Hospital in Forlì between 1997 and 2006 were used for the study. All samples were retrieved from the archives of the Pathology Unit of the same hospital. Median age of patients was 73 years (range 39–92): 31 were <70 years and 43 ≥70 years. On the basis of 2004 World Health Organization criteria, final diagnosis was low grade non muscle invasive bladder cancer (NMIBC) in 55 patients and high grade NMIBC in 19 patients. At a median follow up of 5 years 38 patients were still disease-free and 36 had experienced one or more episodes of local recurrence. In this retrospective study, the two subgroups (disease free or relapsed) of patients were equally distributed for sex, age, grade and stage (Table 1).

All patients gave written informed consent for biological samples to be used for research purposes. The study protocol was reviewed and approved by the ‘Area Vasta’ Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) Ethics Committee.

**Macrodissection and DNA isolation**

Five 5-μm-thick sections were obtained from each paraffin-embedded block. Macrodissection was performed on hematoxylin-eosin stained sections and only cancer tissue was used for DNA isolation. Genomic DNA was purified using QIAamp DNA FFPE Tissue (Qiagen, Milan), according to the manufacturer’s instructions.

DNA was also isolated from a human bladder cancer cell line (HT1376) using Qiamp DNA minikit (Qiagen, Milan, Italy), according to the manufacturer’s instructions.

**Table 2 Summary of gene function and chromosomal localization**

| Gene | Function | Chromosomal localization |
|------|----------|--------------------------|
| TIMP metallopeptidase inhibitor 3 (TIMP3) | Invasion and metastasis | 22q12.3 |
| Adenomatous polyposis coli (APC) | WNT antagonist | 5q22 |
| cyclin-dependent kinase inhibitor 2A (CDKN2A) | Cell-cycle control gene | 9p21 |
| MutL homolog 1, colon cancer, nonpolyposis type 2 (MLH1) | DNA mismatch repair | 3p22.1 |
| Ataxia telangiectasia mutated (ATM) | Cell-cycle control gene | 11q23 |
| Retinoic acid receptor, beta (RARB) | Cell differentiation and proliferation | 3p24.2 |
| Hypermethylated in Cancer 1 (HIC1) | Putative tumor suppressor gene | 17p13.3 |
| Checkpoint with forkhead and ring finger domains (CHFR) | Putative tumor suppressor gene | 12q24.33 |
| breast cancer 1, early onset (BRCA1) | Maintenant of genomic stability | 17q21.31 |
| Caspase 8, apoptosis-related cysteine peptidase (CASP8) | Apoptosis related gene | 2q33.2 |
| Cyclin-dependent kinase inhibitor 1B (CDKN1B) | Cell-cycle control gene | 12p13.2 |
| Phosphatase and tensin homolog (PTEN) | Cell-cycle regulation gene | 10q23.3 |
| Breast cancer 2, early onset (BRCA2) | Maintenance of genomic stability | 13q12.3 |
| CD44 molecule (Indian blood group) (CD44) | Cell-cell interaction mediator | 11p12 |
| Ras association (RalGDS/AF-6) domain family member 1 (RASSF1) | Putative tumor suppressor gene | 3p21.3 |
| Death-associated protein kinase1 (DAPK) | Apoptosis-related gene | 9q34.1 |
| Von Hippel-Lindau tumor suppressor (VHL) | Putative tumor suppressor gene | 3p25 |
| Estrogen receptor 1 (ESR1) | Cell differentiation and proliferation | 6q25.1 |
| Tumor protein p73 (TP73) | Apoptotic response to DNA damage | 1p36.32 |
| Fragile histidine triad gene (FHT) | Putative tumor suppressor gene | 3p14.2 |
| Cell adhesion molecule 1 (IGSF4 (CADM1)) | Cell adhesion related gene | 11q23 |
| Cadherin 13, H-cadherin (heart) (CDH13) | Cell invasion | 16q23.3 |
| Glutathione S-transferase pi 1 (GSTP1) | DNA damage repair gene | 11q13 |
Methylation specific multiple ligation probe amplification (MS-MLPA)

MS-MLPA was performed using at least 50 ng of genomic DNA dissolved in 1XTE buffer (Promega, Madison, WI, USA). DNA isolated from HT 1376 cell line was used as internal control for MS MLPA analysis (Figure 1). The methylation status of 24 tumor suppressor gene promoters was analyzed using the ME001C1 kit (MRC-Holland, Amsterdam, The Netherlands) (Table 2). Two different probes that recognize two different sites of the promoter region were used for genes RASSF1 and MLH. We excluded CDKN2B gene from the analysis because its probe is sensitive to improper Hha1 digestion in FFPE samples. In brief, DNA was denatured (10 min at 98°C) and cooled at 25°C, after which the probe mix was added to the samples and hybridization was performed by incubation at 60°C for 16–18 h. The reaction was divided equally in two vials, one for ligation and the other for ligation-digestion reaction for each tumor. We added a mix composed of Ligase-65 buffer, Ligase-65 enzyme and water to the first vial and a mix of Ligase-65 Buffer, Ligase 65 enzyme, Hha1 enzyme (Promega, UK) and water to the second. The samples were then incubated at 49°C for 30 min. At the end of the ligation and ligation-digestion reactions, samples were amplified by adding a mix of PCR buffer, dNTPs and Taq polymerase. The PCR reaction was performed under the following conditions: 37 cycles at 95°C for 30 sec, 60°C for 30 sec and 72°C for 60 sec. The final incubation was performed at 73°C for 20 min.

Amplification products were analyzed by ABI-3130 genetic Analyzer (Applied Biosystem, UK). Universally methylated and unmethylated genomic DNA was used as positive or negative control, respectively.

Electropherograms obtained were analyzed using Gene Mapper software (Applied Biosystem, UK) and the peak areas of each probe were exported to a home-made excel spreadsheet. In accordance with the manufacturer's instructions, we carried out “intrasample data normalization” by dividing the signal of each probe by the signal of every reference probe in the sample, thus creating as many ratios per probe as there were reference probes. We then calculated the median value of all probe ratios per probe, obtaining the normalization constant (NC). Finally, the methylation status of each probe was calculated by dividing the NC of a probe in the digested sample by the NC of the same probe in the undigested sample, and by multiplying this ratio by 100 to have a percentage value, as follows:

\[
\text{Percentage Methylation} = \left( \frac{\text{NC(digested sample)}}{\text{NC(undigested sample)}} \right) \times 100
\]

MS-MLPA technique reproducibility was assessed by performing three independent methylation profile analyses on a bladder cell line (HT1376). The methylation level for each gene was found to be the same in each experiment.

We considered the promoters showing a ratio ≥0.20 as methylated, while those with a ratio <0.20 were regarded as unmethylated. The cut-off was chosen on the basis of experiments performed on the bladder cancer cell line (HT1376) and on data from the literature [21,22]. We have also performed the analysis on some samples from healthy tissues, to confirm that the background noise was inferior to 0.20 cut-off, such excluding false positive results due to experimental procedure.

### Table 3 Methylation frequencies of different genes in the overall series and in non recurrent or recurrent tumors

| Gene          | Overall series (n = 74) | Non recurrent tumors (n = 38) | Recurrent tumors (n = 36) | P value* |
|---------------|------------------------|-----------------------------|--------------------------|---------|
| CD44          | 1                      | 18                          | 3                        | 0.06    |
| CASP8         | 1                      | 3                           | 0                        | 1       |
| MLH1 (locus 2)| 1                      | 3                           | 0                        | 1       |
| PTEN          | 3                      | 5                           | 0                        | 0.49    |
| VHL           | 3                      | 5                           | 0                        | 0.49    |
| BRC1A2        | 4                      | 8                           | 0                        | 0.24    |
| CHFR          | 4                      | 5                           | 3                        | 1       |
| ATM           | 5                      | 8                           | 3                        | 0.62    |
| BRC2A2        | 5                      | 8                           | 3                        | 0.62    |
| CDKN1B        | 5                      | 5                           | 5                        | 1       |
| RAR1B         | 6                      | 8                           | 6                        | 1       |
| HIC1          | 9                      | 16                          | 0                        | 0.03    |
| FHIT          | 10                     | 1                           | 10                       | 1       |
| MLH1 (locus 1)| 11                     | 15                          | 8                        | 0.48    |
| ESR1          | 12                     | 16                          | 6                        | 0.26    |
| TIMP3         | 13                     | 18                          | 8                        | 0.31    |
| TP73          | 14                     | 19                          | 8                        | 0.19    |
| CDKN2A        | 14                     | 16                          | 14                       | 1       |
| GSTP1         | 15                     | 26                          | 5                        | 0.02    |
| DAPK          | 17                     | 24                          | 8                        | 0.11    |
| IG5F4 (CADM1)| 21                     | 18                          | 25                       | 0.58    |
| RASSF1 (locus 1) | 23                  | 29                          | 14                       | 0.16    |
| APC           | 29                     | 34                          | 25                       | 0.45    |
| RASSF1 (locus2)| 33                    | 45                          | 19                       | 0.03    |
| CDH13         | 50                     | 53                          | 47                       | 0.81    |

*Fisher’s exact test 2-tailed P value (difference between recurrent and non recurrent tumors). Significant genes are highlighted as bold data.
Statistical analysis

Fisher’s exact test was used to compare the frequency of promoter methylation in the two subgroups: recurrent tumors versus non recurrent tumors. Methylation status was considered as a dichotomous variable and genes showing methylation ≥ 20% were classified as positive. A difference was considered significant if it showed a two-tailed $P$ value ≤ 0.05. The genes showing a significant $p$ value in Fisher’s exact test were used to analyze the methylator phenotype. Study endpoints were sensitivity (the proportion of recurrent cancer patients who were correctly identified by the test or procedures) and specificity (the proportion of non recurrent cancer patients who were correctly identified), with their 95% confidence intervals (CIs). We also evaluated overall accuracy, defined as the proportion of the total number of patients correctly identified by the test.

The student’s T test was used to assess the methylation index (MI), which was considered as a continuous variable. Logistic regression analysis was performed using the Epicalc of R to evaluate the performance of a panel of gene promoters (HIC1, RASSF1 and GSTP1) in discriminating between recurrent and non recurrent patients. We created logistic regression models with methylation levels of the three gene promoters (HIC1, RASSF1 and GSTP1). Probabilities were calculated as follows: $P = \exp \left( \frac{\sum (b_i x_i) + c}{1 + \sum (b_i x_i) + c} \right)$, where $p$ is the probability of each case, $i = 1$ to $n$; $b$ is the regression coefficient of a given gene, $x$ is the log2-transformed methylation level and $c$ is a constant generated by the model. The ROCR package was used to obtain the ROC curves of the models and area under the curve (AUC) values. Recurrence-free survival was analyzed with the Log-rank test using SAS 9.3 software. All the molecular analyses were performed in a blind manner.

Results

MS-MLPA analysis was feasible in all samples. The methylation frequency in the overall series varied widely (1% to 50%) for the different genes (Table 3). A separate analysis as a function of recurrence showed lower gene methylation in recurring than non recurring tumors, with the exception of CDKN1B, FHIT and IGSF4 genes. However, a significant difference between recurrent and non recurrent tumors was only observed for GSTP1, HIC1 and RASSF1 locus 2 (Table 3), with lower methylation in relapsed than non relapsed patients (Figure 2). The methylation index (MI), evaluated as the number of methylated genes relative to the total number of analyzed genes, showed values from 0 to 0.68 in the overall series of 23 genes and a significantly lower median value in non recurrent (0.08) than recurrent (0.12) ($P = 0.011$) patients (Table 4). To reduce the complexity of the methodological approach, further analysis was limited to a series of 10 genes (GSTP1, HIC1, RASSF1-locus2, CD44, DAPK, RASSF1-locus1, TP73, BRCA1, ESR1, TIMP3) that

![Figure 2](https://example.com/figure2.png)
proved significant or showed a trend towards significance (P values varying from 0.02 to 0.31). Again, a higher median MI was seen in patients who relapsed compared to those who did not (0 versus 0.2; P = 0.0007) (Table 4).

We constructed a prognostic algorithm with the 3 significant genes (GSTP1, HIC1 and RASSF1) considering two phenotypes: the “methylated phenotype” (MP) (samples with at least one of the three genes methylated), and the “unmethylated phenotype” (samples with none of the three genes methylated). Of the 33 patients with methylated phenotype, 25 (76%) were still disease-free and 8 (24%) had had at least one intravesical recurrence at a median follow up of 5 years (Figure 3). Conversely, of the 41 patients with unmethylated phenotype, 28 (68%) had relapsed within 5 years of surgery and 13 (32%) had remained disease-free. The three-gene panel showed 78% sensitivity in identifying recurrent tumors and 66% specificity, with an overall accuracy of 72%.

We also performed ROC curve analysis for the three significant genes, singly or in combination, considered as continuous variables. Resultant AUCs were 0.5917 for HIC1, 0.6725 for RASSF1 and 0.5409 for GSTP1, the best AUC (0.6959) reached for the combination of the three genes (Figure 4).

Recurrence-free survival analysis of patients with methylated or unmethylated tumors highlighted a significantly higher recurrence-free survival (P = 0.0019) for those whose tumors showed the methylated phenotype (Figure 5).

The recurrence free survival analysis performed considering only the recurrent patients, showed that patients with unmethylated tumors had a lower median recurrent free survival time (14.5 months), with the respect to patients with methylated ones (18 months). However, the two subgroups are not equal distributed to give a statistical significant result (P = 0.9392, data not shown).

Multivariable analysis considering clinical and biological parameters (patient age and sex; tumor grade, stage and size; tumor multiplicity, methylated phenotype) showed that only age and methylated phenotype were independent predictors of recurrence. Specifically, patients

**Table 4 Methylation index analysis**

| Methylation index (MI) | Overall Median value | Recurrence | No recurrence | P value |
|------------------------|----------------------|------------|--------------|---------|
| 23 Genes*              | 0.1                  | 0.08       | 0.12         | 0.011   |
| 10 Genes**             | 0.2                  | 0          | 0.2          | 0.0007  |

*MI = Number of methylated genes/number of analyzed genes.
**MI=number of methylated genes/ 10 genes (GSTP; HIC1; RASSF1 (LOCUS 1); RASSF1 (LOCUS 2); CD44; DAPK; TP73; BRCA1; ESR; TIMP3).

Figure 3 Prognostic algorithm with the three significant genes (GSTP1, HIC1 and RASSF1). Sensitivity was evaluated as the number of recurrent tumors with unmethylated HIC1, RASSF1, GSTP1 relative to the total number of recurrent tumors analyzed. Specificity was evaluated as the number of non recurrent tumors with methylated phenotype relative to the total number of non recurrent tumors analyzed. Overall accuracy was calculated as the number of correctly classified tumors relative to the total number of analyzed tumors.
under 70 years of age showed a higher probability of relapsing than older ones \( P = 0.028 \) and their methylation phenotype was significantly predictive of recurrence \( P < 0.0001 \).

**Discussion**

The present study focused on evaluating the methylation status of tumor suppressor genes and on verifying its role in predicting recurrence of non muscle invasive bladder cancer (NMIBC). The MS-MLPA technique has the advantage of requiring only a small quantity of DNA, is capable of rapidly determining the methylation status of numerous genes in the same experiment, and has also been shown to work well in formalin-fixed paraffin-embedded samples. However, an important limitation of our study was the lack of a sufficient quantity of cancer tissue to confirm the methylation results using a second technique such as methylation specific PCR (MS PCR) or gene expression analyses.

In agreement with results from other studies [18], we found a positive correlation between gene methylation and lack of recurrence, highlighting that putative tumor suppressor genes do not always act as tumor suppressors but may actually have different biological functions.

Statistical analysis revealed 3 genes (HIC1, GSTP1, and RASSF1) capable of significantly predicting tumor recurrence. Their methylation was significantly indicative of a lack of recurrence at the 5-year follow up. The combined analysis of the three genes showed 72% accuracy in predicting recurrence or non recurrence.

HIC1 is a new candidate tumor suppressor gene [23], but the relevance of its methylation in bladder cancer prognosis is still unknown. Although GSTP1 methylation is a well known event in the carcinogenesis of prostate cancer, its role in bladder carcinoma has yet to be defined. A recent study by Pljesa-Ercegovac and coworkers [24] revealed that high GSTP1 expression is associated with an altered apoptotic pathway and bladder cancer progression. As methylation reduces gene expression, our data are in agreement with those of Pljesa-Ercegovac, the absence of GSTP1 methylation observed in our study supporting the hypothesis of more aggressive behavior of bladder tumors and consequently of a higher relapse rate.
Although the role of RASSF1 in bladder cancer development is still unclear, Ha and coworkers reported that its methylation would seem to play a part in predicting recurrence in low grade and stage bladder tumors [25]. Surprisingly, we observed lower methylation levels of RASSF1 in recurrent tumors than in non recurrent ones, the discordance possibly due to different techniques used.

The MS-MLPA approach only permitted us to analyze one CpG site per probe, whereas several CpG sites may have been evaluated by Ha using the MS PCR technique [25]. For these reasons, we believe that further evaluation is needed to clarify the role of RASSF1 in bladder cancer, especially with regard to the correlation between its methylation status and protein expression. We also observed fairly low methylation frequencies for all the loci analyzed compared to those reported in other papers [26]. Such disagreement could again be due to the different analytical techniques adopted and/or to the different case series analyzed. Methylation cannot be the only mechanism of recurrence of NMIBC because the behavior of bladder tumors is fairly heterogeneous, as shown by Serizawa and coworkers [27] who observed an inverse correlation between FGFR mutations and hypermethylation events. In their study of the mechanisms of NMIBC recurrence, Bryan and coworkers [28], identified four reasons for relapse: incomplete resection, tumor cell re-implantation, growth of microscopic tumors and new tumor formation. These mechanisms differ greatly from each other and the identification of a single marker that is common to all four mechanisms appears improbable. It is more likely that a molecular marker characterizes tumor recurrence as a result of the third or fourth mechanisms, which may involve molecular alterations. This might explain why accuracy in our study only reached 72%.

Conclusions

Our preliminary findings pave the way for in depth evaluation of the methylation levels of HIC1, GSTP1, and RASSF1 genes in larger case series to improve the clinical surveillance of patients with superficial bladder cancer.

Consent

Written informed consent was obtained from the patient for the publication of this report and any accompanying images.

Competing interests

The authors declare that they have no competing interests.

Authors’ contributions

VC carried out the molecular genetic studies and drafted the manuscript; CM, DC, MT carried out the molecular genetic studies; RG, LS, FF participated in recruitment of patients and collection and assembly of data; CZ performed statistical analysis; RS helped to draft the manuscript and participated in the design of the study; DA and WZ participated in the design of the study and coordination. All authors read and approved the final manuscript.

Acknowledgements

The authors thank Grainne Thierney and Ursula Elbling for editing the manuscript.

Author details

1Biosciences Laboratory, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS, Via F. Maroncelli 40, Meldola 47014, Italy. 2Department of Urology, Morgagni Pierantoni Hospital, Forlì, Italy. 3Pathology Unit, Morgagni Pierantoni Hospital, Forlì, Italy. 4National Institute of Molecular Genetics, Milan, Italy. 5Department of Medical Oncology, IRST IRCCS, Meldola, Italy.

Received: 16 October 2013 Accepted: 7 November 2013
Published: 19 November 2013

References

1. Van Rhijn BW, Burger M, Lotan Y, Sokona E, Stief CG, Sylvester RJ, et al. Recurrence and progression of disease in non-muscle-invasive bladder cancer: from epidemiology to treatment strategy. Eur Urol 2009, 56(3):430–442.
2. Sharma S, Kelly TK, Jones PA. Epigenetics in cancer. Carcinogenesis 2010, 31(1):27–36.
3. Tao W, Hongli L, Yeshan C, Wei L, Jing Y, Gang W. Methylation associated inactivation of RASSF1A and its synergistic effect with activated K-Ras in nasopharyngeal carcinoma. J Exp Clin Cancer Res 2009, 28:160.
4. Jian Z, Yuyan W, Jianchun D, Hua B, Zhijie W, Lai W. DNA Methylation status of Wnt antagonist SFRPS can predict the response to the EGF-tyrosine kinase inhibitor therapy in non-small cell lung cancer. J Exp Clin Cancer Res 2012, 31:80.
5. Sánchez-Carbayo M. Hypermethylation in bladder cancer: biological pathways and translational applications. Tumour Biol 2012, 33(2):1347–361.
6. Kim WJ, Kim YJ. Epigenetics of bladder cancer. Methods Mol Biol 2012, 863:111–118.
7. Cabello MJ, Grau L, Franco N, Crenes E, Alvarez M, Blanca A, et al. Multiplexed methylation profiles of tumor suppressor genes in bladder cancer. J Mol Diagn 2011, 13(1):29–40.
8. Zuiverloon TC, Beukers W, van der Keur KA, Munoz JR, Bangma CH, Lingsma HF, et al. A methylation assay for the detection of non-muscle-invasive bladder cancer (NMIBC) recurrences in voided urine. BJU Int 2012, 109(6):941–948.
9. Eissa S, Swellam M, El-Kholy M, Kassim SK, Shehata H, Mansour A, et al. Aberrant methylation of RARbeta2 and APC genes in voided urine as molecular markers for early detection of bilateral and nonbilateral bladder cancer. Cancer Epidemiol Biomarkers Prev 2011, 20(8):1657–1664.
10. Negraes PD, Favaro FP, Camargo JL, Oliveira ML, Goldberg J, Rainho CA, et al. DNA methylation patterns in bladder cancer and washing cell sediments: a perspective for tumor recurrence detection. BMC Cancer 2008, 8:238.
11. Hoque MO, Begum S, Brait M, Jeronimo C, Zaharak M, Ostrow NL, Rosenbaum E. Tissue inhibitor of metalloproteinases 3 promoter methylation is an independent prognostic factor for bladder cancer. J Urol 2008, 179(2):743–747.
12. Friedrich MG, Chandrasoma S, Siegmund KD, Weisenberger DJ, Cheng JC, Toma MI, et al: Prognostic relevance of methylation markers in patients with non-muscle invasive bladder carcinoma. Eur J Cancer 2005, 41(7):2769–2778.
13. Tada Y, Wada M, Taguchi K, Mochida Y, Kinugawa N, Tsumeyoshi M, et al. The association of death-associated protein kinase hypermethylation with early recurrence in superficial bladder cancers. Cancer Res 2002, 62(14):4048–4053.
14. Lin HH, Ke HL, Wu WJ, Lee YH, Chang LL: Hypermethylation of E-cadherin, p16, p14, and RASSF1A genes in pathologically normal urothelium

J Exp Clin Cancer Res 2013, 32:94
http://www.jeccr.com/content/32/1/94
predict bladder recurrence of bladder cancer after transurethral resection. *Urol Oncol* 2012, 30(2):177–181.

15. Yates DR, Rehman I, Abbod MF, Meuth M, Cross SS, Linkens DA, et al: Promoter hypermethylation identifies progression risk in bladder cancer. *Clin Cancer Res* 2007, 13(7):2046–2053.

16. Schouten JP, McIlgumn CJ, Waaijer R, Zwijnenburg D, Diepvens F, Pals G: Relative quantification of 40 nucleic acid sequences by multiplex ligation-dependent probe amplification. *Nucleic Acids Res* 2002, 30(12):e57.

17. Nygren AO, Ameziane N, Duarte HM, Vijzelaar RN, Waisfisz Q, Hess CJ, et al: Methylation-specific MLPA (MS-MLPA): simultaneous detection of CpG methylation and copy number changes of up to 40 sequences. *Nucleic Acids Res* 2005, 33(14):e128.

18. Castro M, Grau L, Puerta P, Gimenez L, Venditti J, Quadrelli S, et al: Multiplexed methylation profiles of tumor suppressor genes and clinical outcome in lung cancer. *J Transl Med* 2010, 8:96.

19. Leong KJ, Wei W, Tannahill LA, Caldwell GM, Jones CE, Morton DG, et al: Methylation profiling of rectal cancer identifies novel markers of early-stage disease. *Br J Surg* 2011, 98(5):724–734.

20. Moelans CB, Venshuur-Maes AH, Van Diest PJ: Frequent promoter hypermethylation of BRC2, CDH13, MSH6, PAX5, PAX6 and WT1 in ductal carcinoma in situ and invasive breast cancer. *J Pathol* 2011, 225(2):222–231.

21. Pavicic W, Perkio E, Kaur S, Peltomäki P: Altered methylation at micro RNA-associated CpG islands in hereditary and sporadic carcinomas: a methylation-specific multiplex ligation-dependent probe amplification (MS-MLPA)-based approach. *Mol Med* 2011, 17(7–8):726–735.

22. Joensuu EI, Abdel-Rahman WM, Ollikainen M, Ruosaari S, Knuutila S, Peltomäki P: Epigenetic signatures of familial cancer are characteristic of tumor type and family category. *Cancer Res* 2008, 68(12):4597–4605.

23. Fleuriel C, Touka M, Boulay G, Guérardel C, Rood BR, Leprince D: HIC1 (Hypermethylated in Cancer 1) epigenetic silencing in tumors. *Int J Biochem Cell Biol* 2009, 41(1):26–33.

24. Bryan RT, Collins SI, Daykin MC, Zeegers MP, Cheng KK, Wallace DM, et al: Mechanisms of recurrence of Ta/T1 bladder cancer. *Ann R Coll Surg Engl* 2010, 92(6):S19–S24.

Cite this article as: Casadio et al. DNA Methylation profiles as predictors of recurrence in non muscle invasive bladder cancer: an MS-MLPA approach. *Journal of Experimental & Clinical Cancer Research* 2013 32:94.

Submit your next manuscript to BioMed Central and take full advantage of:

- Convenient online submission
- Thorough peer review
- No space constraints or color figure charges
- Immediate publication on acceptance
- Inclusion in PubMed, CAS, Scopus and Google Scholar
- Research which is freely available for redistribution

Submit your manuscript at www.biomedcentral.com/submit